Australian Indie Fragrance Brand WHO IS ELIJAH Makes U.S. Retail Debut with Revolve

Cult-favorite Australian modern fragrance houseWHO IS ELIJAH is officially making its U.S. retail debut. Beginning October 31, 2025, the minimalist, genderless fragrance brand will launch exclusively with Revolve, marking a milestone moment as it expands beyond its Australian roots. https://mma.prnewswire.com/media/2809833/Who_is_Elijah_NEW_Logo.jpg Founded seven years ago by Creative Director & Founder Raquel Bouris, WHO IS ELIJAH has […]

Tidal League Expands U.S. Operations to The Star in Frisco, Partnering with Frisco EDC to Strengthen Sports City USA’s Ecosystem

Tidal League, a leading athlete-driven media company, today announced the expansion of its U.S. operations to The Star in Frisco, establishing a new content studio in the heart of Sports City USA. Supported by the Frisco Economic Development Corporation (Frisco EDC), the move marks a major milestone in Tidal League's growth and further elevates Frisco's

eDesign Interactive Unveils New Website for EdgarAgents, Showcasing Speed, Precision, and Client-Focused Service

eDesign Interactive's redesign of EdgarAgents' website highlights the firm's commitment to speed, compliance, and an enhanced client experience. eDesign Interactive, an award-winning web design and digital marketing agency, has recently launched a redesigned website for EdgarAgents, a leading SEC filing and financial printing firm. The new website reflects EdgarAgents' reputation for speed, precision, and compliance,

Galan Lithium – Quarterly Activities Report September 2025

Highlights Successful completion of due diligence by the Clean Elements Fund ("Clean Elements") confirming HMW’s world-class status; $20 million placement to proceed with full and final settlement due by November. RIGI incentive regime approved by the Argentine Government for the HMW Project, providing fiscal stability and significant long-term benefits. Advancement of Phase 1 construction at

60 Degrees Pharmaceuticals and NDT Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FLORIDA / ACCESS Newswire / October 31, 2025 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) and NDT Pharmaceuticals Inc. (OTC:NDTP) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, November 1, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in

Sanitation Strategies Launches LABSAN PEROXISAN™ TB RTU – A Ready-to-Use Hydrogen Peroxide Disinfectant with 1-Minute Kill on TB and Corynebacterium bovis

Sanitation Strategies, LLC, a leader in innovative sanitation products and services for the biomedical research industry, today announced the launch of LABSAN PEROXISAN™ TB Ready-to-Use, a hydrogen peroxide disinfectant and EPA-registered tuberculocide designed for rapid, broad-spectrum disinfection in animal care and research environments. https://mma.prnewswire.com/media/2809688/Sanitation_Strategies_Labsan_Peroxisan_TB_RTU_Product_Line.jpg This latest addition to Sanitation Strategies' growing LABSAN product line delivers

NAVEE Launches XT5 Pro All-Terrain Electric Scooter, Expanding Green Mobility Beyond the City

NAVEE, a leading innovator in smart mobility, today unveils the XT5 Pro All-Terrain Electric Scooter, designed for riders seeking both performance and sustainability. The XT5 Pro will be available through NAVEE's official online store and Amazon, priced at $1,499.99. Built for exploration, the XT5 Pro features a 2,200 W high-torque rear motor, delivering 30% more

A positive cycle of development and opening-up: Powering a new chapter for China

A news report fromChina.org.cn on China's 15th Five-Year Plan: In Arnstadt, a little city in Thuringia, central Germany, a modernized battery plant set up by Chinese company CATL is running in full swing. The city, once a hub for Germany's traditional automobile industry, has been reinvigorated by green technology, and the battery plant is now

Zhimeng Biopharma’s investigational drug CB03-154 for amyotrophic lateral sclerosis has achieved the first patient first dose milestone in the phase 2/3 pivotal clinical trial.

Shanghai Zhimeng Biopharma Inc. ( “Zhimeng”) announced that its self-developed new-generation potassium channel opener CB03-154 for the treatment of amyotrophic lateral sclerosis (ALS) has officially initiated the phase 2/3 clinical trial and completed the first patient first dose at the 2nd Affiliated Hospital of Hebei Medical University. Previously (in July 2025), CB03-154 received approval from

Scroll to Top